Mesenchymal stem cell therapy - Translational Biosciences

Drug Profile

Mesenchymal stem cell therapy - Translational Biosciences

Alternative Names: Mesenchymal Trophic Factor; Mesenchymal Trophic Factor - Translational Biosciences; Trophic factors from umbilical cord mesenchymal stem cells; Trophic factors from umbilical cord mesenchymal stem cells - Translational Biosciences

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Translational Biosciences
  • Class Antirheumatics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple sclerosis; Osteoarthritis

Most Recent Events

  • 26 Apr 2017 Translational Biosciences withdraws a phase-I/II clinical trials in Osteoarthritis in Panama due to no enrollment (Intra-arterial) (SC) (NCT02003131)
  • 17 Mar 2016 Mesenchymal stem cell therapy is still in phase I/II trials for Osteoarthritis and Multiple sclerosis in Panama
  • 09 Jan 2014 Phase-I/II clinical trials in Multiple sclerosis in Panama (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top